ReviewGastroenterology research and practice2014
Incidence and paris classification of pediatric inflammatory bowel disease.
Review in Gastroenterology research and practice, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 53 citations in OpenAlex.
- Therapy de-escalation in paediatric patients with inflammatory bowel disease in remission: Data analysis from the CEDATA registry.Journal of pediatric gastroenterology and nutrition · 2026Article
- Microbial signature of pediatric Crohn's disease: Differentiation from functional gastrointestinal disorders and relationship with increased disease activity.Physiological reports · 2026Article
- Inflammatory bowel disease in paediatrics: Navigating the old challenges and emerging frontiers.World journal of gastroenterology · 2025Review
- Evaluation of Growth in Children with Inflammatory Bowel Disease.Children (Basel, Switzerland) · 2024Article
- Efficacy of short-chain polypeptide-based EEN formulas in alleviating intestinal injury in children with Crohn's disease: a single-center study in China.Frontiers in nutrition · 2023Article
- Clinical and lifestyle patterns in Asian children with inflammatory bowel disease in the U.S.PloS one · 2023Article
- Evaluation of Fecal Calprotectin, Serum C-Reactive Protein, Erythrocyte Sedimentation Rate, Seromucoid and Procalcitonin in the Diagnostics and Monitoring of Crohn's Disease in Children.Journal of clinical medicine · 2022Article
- Therapeutic Advances in Gut Microbiome Modulation in Patients with Inflammatory Bowel Disease from Pediatrics to Adulthood.International journal of molecular sciences · 2021Review
- Biomarkers for Optimization and Personalization of Anti-TNFs in Pediatric Inflammatory Bowel Disease.Pharmaceutics · 2021Review
- Magnetic resonance imaging in the management of Crohn's disease: a systematic review and meta-analysis.Insights into imaging · 2021Review
- A Feeling of Otherness: A Qualitative Research Synthesis Exploring the Lived Experiences of Stigma in Individuals with Inflammatory Bowel Disease.International journal of environmental research and public health · 2021Review
- Endoscopic and Histologic Predictors of Outcomes in Pediatric Ulcerative Colitis-Frontiers in pediatrics · 2021Review
- Development of peripheral eosinophilia in inflammatory bowel disease patients on infliximab treated at a tertiary pediatric inflammatory bowel disease center is associated with clinically active disease but does not result in loss of efficacy or adverse outcomes.JGH open : an open access journal of gastroenterology and hepatology · 2020Article
- Enteric Virome and Bacterial Microbiota in Children With Ulcerative Colitis and Crohn Disease.Journal of pediatric gastroenterology and nutrition · 2019Article
- Extensive Disease Subtypes in Adult Patients with Ulcerative Colitis: Non-pancolitis Versus Pancolitis.Digestive diseases and sciences · 2018Article
- Regulation of Nuclear Factor Kappa-Light-Chain-Enhancer of Activated B Cells (NF-κβ) in Inflammatory Bowel Diseases.Frontiers in pediatrics · 2018Review
- Tumor necrosis factor α-induced protein 3 (A20) is dysregulated in pediatric Crohn disease.Clinical and experimental gastroenterology · 2018Article
- ROS in gastrointestinal inflammation: Rescue Or Sabotage?British journal of pharmacology · 2017Review
- Genetic disorders coupled to ROS deficiency.Redox biology · 2015Review
- Characteristics of Pediatric Inflammatory Bowel Disease in Korea: Comparison with EUROKIDS Data.Gut and liver · 2015Article
Corrections and comments
- Erratum issued
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
New epidemiological data suggest that the incidence of inflammatory bowel disease (IBD) is increasing. As a result the burden of disease accounts for more strains to the health care system. The clinical variability queries whether disease characteristics are related to clinical outcome. Our aim was to delineate the latest results of incidence trends in pediatric IBD and to compare the first experiences with Paris Classification. Incidence of pediatric IBD has been increasing in Western Europe and in Eastern Europe. To better characterize IBD, Paris Classification was introduced and validated recently. Ileocolonic involvement is the most characteristic disease location in Crohn's disease (CD) based on applying Paris Classification. The rate of perianal disease and complicated behaviour in CD was similar. It is of interest that CD patients with colonic involvement were less likely to have stricturing disease compared with patients with ileal involvement. In addition, pancolitis dominated in ulcerative colitis (UC). However, most countries lack prospective, nationwide epidemiological studies to estimate incidence trends. This review emphasizes the importance of nationwide registries that enroll all pediatric IBD cases serving reliable data for "everyday practice." These first reports have shown that Paris Classification is a useful tool to determine the pediatric IBD phenotype.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.